Author

M. Vierhout

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pathology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

K. Ask· 2 shared M. Kolb· 2 shared O. Mekhael· 2 shared S. Naiel· 2 shared A. Ayoub· 1 shared A. B. Montgomery· 1 shared A. Dvorkin-Gheva· 1 shared A. Hayat· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

K. Ask

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship

G. Epstein-Shochet, S. Pham, S. Beck, S. Naiel, O. Mekhael, S. Revill, A. Hayat, M. Vierhout, B. Bardestein-Wald, D. Shitrit, K. Ask, A. B. Montgomery, M. Kolb, M. Surber

This paper investigates the pharmacokinetic/pharmacodynamic relationship of inhaled nintedanib for IPF treatment, showing that short-duration inhaled doses can achieve equivalent or superior efficacy compared to long-duration oral doses.

bioRxiv · Mar 27, 2020Pharmacology & Toxicology

FK506-binding protein 13 expression is upregulated in interstitial lung disease and correlated with clinical severity: a potentially protective role.

V. Tat, E. A. Ayaub, A. Ayoub, M. Vierhout, S. Naiel, M. Padwal, S. Abed, O. Mekhael, K. Tandon, S. D. Revill, T. Yousof, P.-S. Bellaye, P. Kolb, A. Dvorkin-Gheva, A. Naqvi, , K. Ask

This study shows FKBP13 is upregulated in interstitial lung diseases and correlates with disease severity, suggesting a protective role against fibrosis.

bioRxiv · Dec 15, 2019Pathology